Bloomer Aaron 4

What Happened

• Aaron Bloomer, CFO of Exact Sciences (EXAS), had 89,911 restricted/performance units deemed vested/awarded and recorded as an acquisition on 2026-03-23, and transferred a total of 171,554 shares (including derivative-based RSU/PSU interests) to the issuer/merger subsidiary the same day. Under the merger terms, each share was converted into the right to receive $105.00 in cash. The 89,911-unit award is worth about $9.44 million (89,911 × $105); the shares transferred total about $18.01 million (171,554 × $105). Payments are subject to applicable tax withholding.

Key Details

• Transaction date: March 23, 2026 (filing accession 0001193125-26-118759 filed same day).
• Price / consideration: $105.00 per share in cash under the Merger Agreement with Abbott Laboratories.
• Reported entries: A (award/acquisition) of 89,911 units @ $0.00; D (dispositions to issuer) of 138,679; 417; 4,395 (derivative); and 28,063 (derivative) — total dispositions = 171,554 shares.
• Shares owned after transaction: not specified on the provided Form 4 excerpt.
• Footnotes: conversions and cash payments arose from the Merger Agreement (Nov 19, 2025). PSUs/RSUs outstanding before the merger were deemed vested/converted to cash; certain RSUs granted on/after Nov 19, 2025 were assumed by Parent on adjusted terms. Payments are net of tax withholding.

Context

• These were not open-market sales but merger-related cash-outs: outstanding equity awards and common shares were canceled/converted into a cash merger consideration ($105/share) when Abbott completed its acquisition of Exact Sciences. Such transactions reflect deal mechanics rather than a routine insider sale or purchase.